Alkermes share price logo

Alkermes

NASDAQ: ALKS

Mid Cap

$45.97

-0.14

(-0.30%)

as on

Alkermes Stock Performance

as on September 14, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $45.73
    $46.75
    downward going graph

    0.52%

    Downside

    1.70%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $26.40
    $55.67
    downward going graph

    42.57%

    Downside

    21.10%

    Upside

    downward going graph

Alkermes share price movements today

Previous Close
$46.11
Open
$46.75
Volume
927.0K
Market Cap
$7.6B
Day's Low - High
$45.73 - $46.75
52 Week Low - High
$26.40 - $55.67

Alkermes Historical Returns

1 Month Return
-8.1 %
3 Month Return
+ 3.56 %
1 Year Return
+ 68.59 %
3 Year Return
+ 57.37 %
5 Year Return
+ 48.75 %

Alkermes Stock Fundamentals & Key Indicators

Check Alkermes market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.6B

EPS (TTM)

0.403

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.99%

PE Ratio (TTM)

112.66

Industry PE ratio

28.00

PEG Ratio

-1.3855280796326406

EBITDA

218.0M

Revenue (TTM)

1.7B

Profit Margin

84.56%

Return On Equity TTM

3.72%

Alkermes Stock Valuation

Track how Alkermes P/E has moved over time to understand its valuation trends.

Alkermes in the last 5 years

  • Overview

  • Trends

Lowest (-77.72x)

December 31, 2021

Today (19.03x)

December 31, 2025

Industry (28.00x)

December 31, 2025

Highest (19.03x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 19.03x

Alkermes vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alkermes with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$7.6B48.75%112.6684.56%NA
BUY$21.7B141.04%16.7786.14%NA
HOLD$19.4B19.57%-45.8334.83%288.98%
BUY$40.9BNA18.8814.55%134.02%
BUY$31.3B-64.58%12.0670.87%284.12%

Stock Returns calculator for Alkermes Stock including INR - Dollar returns

The Alkermes stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Alkermes investment value today

Current value as on today

₹1,85,091

Returns

₹85,091

(+85.09%)

Returns from Alkermes Stock

₹70,702 (+70.7%)

Dollar Impact

₹14,389 (+14.39%)

Analyst Recommendation on Alkermes Stock

Based on 12 analysts

BUY

75.00%

Buy

16.67%

Hold

8.33%

Sell

Based on 12 analysts, 75% of analysts recommend a 'BUY' rating for Alkermes. Average target price of $56

Alkermes Share Price Target

Get share price movements and forecasts by analysts on Alkermes.

What analysts predicted

17.91%UPSIDE

Target Price

$56

Current Price

$45.97

Analyzed by

12 Analysts

Target

$56.00

Alkermes target price $56, a slight upside of 17.91% compared to current price of $45.97. According to 12 analysts rating.

Indian Investors' Interest in Alkermes Stock

Search interest for Alkermes Stock has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-42% versus previous 30 day period

Alkermes Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
350
399
378
429
306
390
394
384
392
496
Gross Profit
291
337
315
367
257
341
342
338
331
397
Operating Income
43
109
104
162
13
92
89
58
-48
18
EBITDA
60
129
123
181
32
112
108
76
-21
54
Interest Expense
5
5
6
4
-
-
-
12
20
25
Depreciation
8
6
6
6
7
7
8
3
19
30
Income Before Tax
46
116
110
169
25
104
100
60
-61
-1
Income Tax Expense
7
22
17
24
3
17
17
11
4
-2
Net Income
36
91
92
146
22
87
82
49
-66
0
Net Profit Margin
83.26%
84.60%
83.31%
85.55%
83.95%
87.34%
86.91%
87.98%
84.33%
80.22%

Alkermes Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
903
1,094
1,170
1,038
1,173
1,111
1,663
1,557
1,475
Gross Profit
748
917
990
860
976
893
1,410
1,312
1,279
Operating Income
-147
-99
-175
-112
97
-6
414
420
253
EBITDA
-32
-7
-103
-6
177
59
519
494
330
Interest Expense
12
15
13
8
11
13
23
22
12
Depreciation
98
103
80
81
78
77
74
28
27
Income Before Tax
-143
-126
-197
-96
87
-31
421
443
291
Income Tax Expense
14
12
0
14
11
2
-97
71
49
Net Income
-157
-139
-196
-110
-48
-158
355
367
241
Net Profit Margin
82.87%
83.88%
84.59%
82.83%
83.19%
80.39%
84.79%
84.25%
86.69%

Alkermes Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
36
94
92
146
22
87
82
49
-
0
Operating Cash Flow
21
146
81
190
98
150
101
170
-165
145
Investing Cash Flow
-39
51
-109
-13
9
-29
-6
322
-2,077
-2
Financing Cash Flow
-17
-83
-111
-281
0
0
0
10
1,474
17
Change in Cash
-36
114
-138
-105
108
121
95
503
-768
159

Alkermes Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-157
-139
-196
-110
-48
-158
355
367
241
Operating Cash Flow
19
99
72
82
101
21
401
439
520
Investing Cash Flow
-18
-22
-141
-11
-66
-64
53
-111
295
Financing Cash Flow
4
-1
6
-2
29
-1
-289
-494
12
Change in Cash
4
75
-62
69
64
-45
164
-166
828

Mutual Funds that own Alkermes Stock

Check out the Mutual Funds with significant holdings in Alkermes.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.816534%
13113275
JPMorgan Trust II
1.57679%
2645276
DFA INVESTMENT DIMENSIONS GROUP INC
1.212861%
2034736
Fidelity Concord Street Trust
1.106538%
1856366
TIAA-CREF Funds
1.063948%
1784915

Global Institutional Holdings in Alkermes

Funds
Holdings
iShares
12.36%
Vanguard
9.38%
Felix Baker
5.97%
SPDR
3.49%
Theofanis Kolokotrones
1.51%

Alkermes News & Key Events

  • img

    Today's Timeline - 13 July

    Mon, 07:31 PM

    -

    JPMorgan resumes coverage of Alkermes with a Neutral rating and $60 price target, noting its role in the sleep space.

    Mon, 08:36 PM

    -

    Alkermes stock down 1.48% as momentum weakens; trading above key moving averages despite recent declines.

Insights on Alkermes

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -66.48M → 501.0K (in $), with an average increase of 13369.5% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 384.54M → 496.00M (in $), with an average increase of 11.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ALKS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, ALKS stock has moved up by 65.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 68.0% return, outperforming this stock by 14.0%

About Alkermes

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
OrganisationAlkermes
HeadquartersConnaught House, Dublin, Ireland, D04 C5Y6
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Blair C. Jackson
E-voting on sharesClick here to vote

Key Management of Alkermes

Name

Title

Mr. Samuel J. Parisi

Interim Principal Accounting Officer & VP of Finance

Mr. Tom Skoff

SVP & Chief Information Officer

Mr. Stephen Schiavo

Senior VP & Chief Human Resources Officer

Mr. David Joseph Gaffin J.D.

Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary

Mr. Joshua Reed M.B.A.

Senior VP & CFO

Dr. Craig C. Hopkinson M.D.

Executive VP of Research & Development and Chief Medical Officer

Mr. Christian Todd Nichols

Senior VP & Chief Commercial Officer

Ms. Sandra Coombs

Senior Vice President of Corporate Affairs & Investor Relations

Mr. Peter Norman

SVP of Policy, Government & Community Relations

Mr. Blair C. Jackson

CEO & Director

FAQs

What is Alkermes share price today?

Alkermes share price today is $45.97 as on at the close of the market. Alkermes share today touched a day high of $46.75 and a low of $45.73.

What is the 52 week high and 52 week low for Alkermes share?

Alkermes share touched a 52 week high of $55.67 on and a 52 week low of $26.40 on . Alkermes stock price today i.e. is closed at $45.97,which is 17.42% down from its 52 week high and 74.13% up from its 52 week low.

What is Alkermes's market capitalisation today?

Alkermes market capitalisation is $0.01T as on .

How to invest in Alkermes Stock (ALKS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Alkermes on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alkermes Shares that will get you 0.0326 shares as per Alkermes share price of $45.97 per share as on September 14, 2026 at 8:45 am IST.

What is the minimum amount required to buy Alkermes Stock (ALKS) from India?

Indian investors can start investing in Alkermes (ALKS) shares with as little as ₹95.55 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.50 in Alkermes stock (as per the Rupee-Dollar exchange rate as on ). Based on Alkermes share’s latest price of $45.97 as on September 14, 2026 at 8:45 am IST, you will get 0.2175 shares of Alkermes. Learn more about fractional shares .

What are the returns that Alkermes has given to Indian investors in the last 5 years?

Alkermes stock has given 48.75% share price returns and 29.74% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?